| Particulars (Rupees in Crores.) | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 | Dec-2023 |
|---|---|---|---|---|---|
Gross Sales | 1,813.7 | 1,742.2 | 1,720.4 | 1,746.4 | 1,665.2 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,813.7 | 1,742.2 | 1,720.4 | 1,746.4 | 1,665.2 |
Other Operating Income | 8 | 10.1 | 11.3 | 12.2 | 11.9 |
Other Income | 9.2 | 21.7 | 409.9 | 17.8 | 48.9 |
Total Income | 1,830.9 | 1,774 | 2,141.6 | 1,776.4 | 1,726 |
Total Expenditure | 1,553.5 | 1,477.2 | 1,480.2 | 1,656.1 | 1,459.1 |
PBIDT | 277.4 | 296.8 | 661.4 | 120.3 | 266.9 |
Interest | 55.6 | 61 | 71 | 73 | 71.3 |
PBDT | 221.8 | 235.8 | 590.4 | 47.3 | 195.6 |
Depreciation | 91.3 | 91.4 | 90.7 | 101 | 94.6 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 32.3 | 40 | 26.1 | 108.1 | 45.1 |
Deferred Tax | -2.5 | 1.9 | -8.2 | -100 | -10.5 |
Reported Profit After Tax | 100.7 | 102.5 | 481.8 | -61.8 | 66.4 |
Minority Interest After NP | -0.2 | -0.3 | -0.3 | -3.2 | -0.4 |
Net Profit after Minority Interest | 100.9 | 102.8 | 482.1 | -58.6 | 66.8 |
Extra-ordinary Items | -14.22 | -10.08 | 375.22 | -60.8 | 0 |
Adjusted Profit After Extra-ordinary item | 115.12 | 112.88 | 106.88 | 2.2 | 66.8 |
EPS (Unit Curr.) | 6.37 | 6.47 | 30.44 | -3.69 | 4.22 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 15.8 | 15.8 | 15.8 | 15.8 | 15.8 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 15.29 | 17.03 | 38.44 | 6.88 | 16.02 |
PBDTM(%) | 12.22 | 13.53 | 34.31 | 2.7 | 11.74 |
PATM(%) | 5.55 | 5.88 | 28 | -3.53 | 3.98 |
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
